We used accelerator mass spectrometry (AMS) and 26 Al to study the plasma concentration, urinary excretion, and retention in bone, brain, and liver of a single dose of a dietary concentration of aluminum ingested either with or without citrate by 2-month-old Wistar rats. In the absence of citrate, cumulative urinary excretion and skeleton retention were each ϳ0.05% of the total 26 Al dose ingested. 26 Al retention in brain and liver were ϳ4 ؋ 10 ؊8 and 2 ؋ 10 ؊6 , respectively. Concomitant citrate intake increased these median values by about two-to fivefold, although this factor was highly variable in individual rats. Independent of citrate administration, 90% of the 26 Al excreted in urine (measured cumulatively over 30 days) was excreted within the first 48 h. Uptake by bone was rapid (ϳ1 h) and permanent over the 30-day duration of the experiment. The potentially toxic effects of aluminum (Al)-encephalopathy, osteomalacia, microcytic anemia-became apparent during the treatment of patients suffering from chronic renal failure [1] [2] [3] [4] . The Al in question came from excessive amounts of this trace element in dialysis fluids, or from its intestinal absorption linked to the administration of massive oral doses in medications given for treatment of hyperphosphatemia. This raises the question of whether the much smaller quantities of Al from normal dietary intake could, under special conditions, be a contributing factor to related diseases in the general population, including Alzheimer disease [5, 6] .
The potentially toxic effects of aluminum (Al)-encephalopathy, osteomalacia, microcytic anemia-became apparent during the treatment of patients suffering from chronic renal failure [1] [2] [3] [4] . The Al in question came from excessive amounts of this trace element in dialysis fluids, or from its intestinal absorption linked to the administration of massive oral doses in medications given for treatment of hyperphosphatemia. This raises the question of whether the much smaller quantities of Al from normal dietary intake could, under special conditions, be a contributing factor to related diseases in the general population, including Alzheimer disease [5, 6] .
At rates of ordinary dietary intake, the low intestinal absorption of Al, its preexisting concentrations in all tissues, and ubiquitous laboratory contamination, all make kinetic studies with 27 Al, the only stable isotope, very difficult, if not impossible [1] . The obvious solution, namely, the use of a radioactive isotope, was until recently not practical because the half-lives of the available isotopes were either too short (Ͻ7 min) or too long (716 000 years). The development of accelerator mass spectrometry (AMS) has now made feasible the use of the latter isotope, 26 Al [7] [8] [9] [10] , although at present in only a few highly specialized centers.
In a previous study [11, 12] , we used AMS to determine the fraction of 26 Al ingested by rats that was transiently present in plasma, excreted in urine, or retained in bone 8, 24 , and 48 h after oral intake. Somewhat surprisingly, we found that the fraction retained in bone (ϳ0.02%) was about the same as that excreted in urine after the administration of a single dose. Another surprising result was that, taking into account sample-to-sample variability, and the limited number of rats studied, we were unable to confirm a statistically significant enhancing effect of concomitant ingestion of citrate on Al absorption, in contrast to reports by other workers [13] [14] [15] [16] [17] [18] [19] .
In the present work, our previous study has been expanded in two directions: (a) We have extended the period considered from 0.5 h to 30 days after ingestion; and (b) we have added brain and liver to the organs studied (in the previous study we gave only upper limits for 26 Al accumulation in the liver).
Materials and Methods
Forty normal male Wistar AF rats (mean Ϯ SD body weight, 301 Ϯ 52 g) were separated into two groups and had free access to diet before and during the experiment (diet no. AO4, distributed by UAR, Villemoisson sur Orge, France). Twenty rats received an oral gavage of 100 L of a solution containing 3.8 ng of 26 Al and 63 ng of 27 Al (in a weak HCl solution) plus 300 L of distilled water (first group). Another 20 rats underwent oral gavage of 100 L of the same solution but with 300 L of citric acid solution (62 g/L), i.e., approximately the normal dietary intake of citrate by rats [20] (second group). The pH of the two ingested solutions was respectively 1.92 and 1.67, near that of normal stomach acidity. Aortic blood, liver, brain, and femur samples were obtained by killing two rats in each group at each time point, i.e., at 0.5, 1, 1.5, 2, 4, 6, 8, 120, 360, and 720 h after gavage. Cumulative urine samples (two per group) were obtained: (a) for 8 h for the rats killed at 8 h; (b) each 24 h during 120 h for the rats killed on day 5; (c) at 0 -120 h and 120 -360 h for the rats killed on day 15; (d) and at 0 -120, 120 -696, and 696 -720 h for the rats killed on day 30.
Animal handling and experimentation conformed to guidelines issued by the European Economic Community, as published in Journal Officiel des Communautés Européennes (Déc 18) 1986; L358.
Samples consisted of 1 mL of blood plasma, total brain, a fraction of the liver, one femur cleaned of adhering matter, and a fraction of total urinary volume; all were treated according to the experimental protocol described elsewhere [11] . The 26 Al/ 27 Al ratios of the resulting Al 2 O 3 were measured by using the "Tandetron" AMS facility at Gif/Yvette, France [8] .
All results are expressed as the 26 Al present in total plasma, bone, cumulative urine, brain, and liver divided by the ingested 26 Al for each rat. The fractions are sometimes expressed as %. Measurement uncertainties were generally ϳ10%, except for the brain samples, for which the statistical error increased to 15-30% or, in three cases, permitted us to report only an upper limit. To convert the 26 Al present in measured samples to the 26 Al present in the total volume of blood (or plasma) or in the total skeleton, we used the following estimations.
Total plasma volume (V p ), in milliliters, was calculated
38, where W is rat body weight in grams. Total blood volume was calculated by assuming a hematocrit of 50% [22] for rat blood.
Skeleton was assumed to represent 8% of rat body weight [23] , and the 26 Al concentration observed in the femur was assumed to be representative of the content in the whole skeleton.
We used the nonparametric Mann-Whitney U-test to examine the statistical significance of differences between rats treated either with or without citrate. Because of the relatively small number of animals at each time point, results have been expressed throughout both as median values (with range) and as mean Ϯ SD.
Results

circulating 26 al values
The fraction of administered 26 Al present in total plasma as a function of time is presented in Fig. 1 . For the rats treated without citrate, the 26 Al present in plasma appeared to reach a maximum (near 0.01%) between 1 and 2 h after ingestion, and decreased by more than three orders of magnitude (10 Ϫ3 ) after 1 month. For rats treated with citrate, the 26 Al concentration in plasma apparently peaked before the first time point of 30 min (with a value of ϳ0.1% at 30 min). From this maximum value to the value observed at 1 month was a decrease of 10 Ϫ4 . To investigate the fraction of 26 Al in blood associated with components other than plasma, we also measured whole-blood aliquots from the rats killed at 1 h after gavage. The plasma results accounted for 70% of the 26 Al in blood after gavage without citrate, and ϳ85% after gavage with citrate.
urinary
26 al elimination Figure 2 shows the distribution of urinary 26 Al excretion as a function of time for rats killed after 5, 15, or 30 days. In the last-named group, ϳ94% of cumulative 26 Al was excreted after 5 days, ϳ6% in the next 24 days, and ϳ0.1% during the final (30th) day. Results were similar for the rats killed on day 15, again with ϳ95% of the 26 Fig. 1 . Fraction of administered 26 Al in total plasma volume of rats after the oral ingestion of 26 Al without citrate (Ⅺ) or with citrate (ࡗ).
Al being
Plasma was obtained 0.5, 1, 1.5, 2, 4, 6, 8, 120, 360, or 720 h after ingestion, from two rats per time point. Note log-scale of abscissa.
excreted during the first 5 days. For the rats killed on day 5, ϳ90% of cumulative 26 Al excretion took place within 24 h, and ϳ95% within 48 h. Together, these data show that ϳ90% of cumulative urinary excretion occurs during the first 48 h after ingestion, with or without the concomitant ingestion of citrate. Thus, a cumulative 48-h urine sample can be used to make a convenient and reliable estimate of total urinary excretion after the administration of a single oral dose. Figure 3c summarizes the cumulative urine data. The values found in rats treated with citrate were both greater and more variable than those in rats without citrate. From the time profiles seen in plasma, one might argue that at least part of the difference at 8 h could result from a more rapid absorption and excretion of 26 Al in the rats treated with citrate. Therefore, for purposes of comparison, we considered only the results at 5, 15, and 30 days (n ϭ 6). The resulting median values were 16.4 ϫ 10 Ϫ4 (range, 9.4 -91 ϫ 10 Ϫ4 ; mean Ϯ SD, 28 Ϯ 32 ϫ 10 Ϫ4 ) for rats with citrate and 5.6 ϫ 10 Ϫ4 (range, 2.5-6.8 ϫ 10 Ϫ4 ; mean Ϯ SD, 5.2 Ϯ 1.8 ϫ 10
Ϫ4
) for rats without citrate. Thus, an enhancement effect of about threefold (P Ͻ0.005) was associated with the citrate ingestion.
bone
26 al accumulation Figure 3d shows an estimate of the fraction of ingested 26 Al retained in the whole skeleton, for each of the 40 rats studied, according to measurement of femur 26 Al. There is no strong correlation of amounts of Al ingested-either with citrate (r 2 ϭ 0.01) or without citrate (r 2 ϭ 0.05)-as a function of time. This indicates that 26 Al uptake into bone took place very rapidly (ϳ1 h) and irreversibly (at least within the 30 days studied). The median value of the 20 determinations in rats without citrate was 4. ) in rats with citrate. Thus, the concomitant intake of 26 Al with citrate increased the accumulation of 26 Al in bone by a factor of ϳ5 (P Ͻ0.0002, n ϭ 20 for each group).
brain and liver 26 al accumulation
The fractions of 26 Al observed in brain and liver at Ն8 h are presented in Fig. 3(a, b) . We also measured some samples from animals killed at earlier time points. However, because we made no special effort to remove blood from the blood vessels of these organs, we cannot neglect a contribution from this source at the earlier times. In fact, on the basis of our measured plasma 26 Al concentrations, we calculate that a vascular blood component of ϳ20% and ϳ5% for liver and brain, respectively, would be sufficient to explain the total 26 Al observed in these organs Ͻ8 h after gavage-plausible fractions under our experimental conditions. We thus restricted ourselves to using only the results from 5, 15, and 30 days after ingestion. The median fraction of 26 Al retained in the brain was 3.8 ϫ 10 Ϫ8 (range, 0.8 -6.5 ϫ 10
Ϫ8
; mean Ϯ SD, 3.7 Ϯ 1.1 ϫ 10 Ϫ8 ) (n ϭ 6, using upper limits for 3 of these values) in rats that received no citrate, and 5.8 ϫ 10 Ϫ8 (range, 3.2-46 ϫ 10
; mean Ϯ SD, 13.1 Ϯ 18.5 ϫ 10 Ϫ8 ) (n ϭ 5) in rats that had received citrate treatment.
Using the same reasoning, we determined that the respective fractions of 26 Al retained in liver were 2. ), respectively (n ϭ 6 each group). Thus for these two tissues, at the times when blood 26 Al contribution was negligible, the concomitant intake of citrate led to a moderate median increase (twofold) in aluminum retention in the liver and brain. Given the limited number of data, and the fact that only upper limits were available for 3 brain samples, this increase was not statistically significant (P Ͼ0.1).
Discussion
In contrast to our earlier study [11] , the present work gives clear evidence that concomitant ingestion of citrate leads to a modest, but statistically significant, increase in Al absorption. We have no obvious explanation for this discrepancy and believe it may be simply due to the limited number of rats studied in the earlier experiment, Clinical Chemistry 43, No. 6, 1997 as well as the relatively large variability in the absorption factor, particularly for Al ingested with citrate.
The present study confirms our earlier observation that the amount of ingested Al retained by bones in young rats is as great as that excreted in urine. The accumulation in the skeleton also appears to be relatively permanent. For example, by comparing the amount of 26 Al excreted in urine after 30 days with that accumulated in bone in the same rats, one can calculate a lower limit (because not all excreted 26 Al is necessarily from bone) of 500 days for the residence time in bone. It will be important to investigate whether similar results are observed for older rats, where bone growth is considerably slower.
The only other experiments using 26 Al and rats that, to our knowledge, can be directly compared with ours, are those of Schö nholzer et al. [16, 17] and Ittel et al. [24] . The former investigators found urinary excretion for 26 Al ingested as Al(OH) 3 to be 0.07-0.11%, only slightly more than our value of 0.05% for gavage without citrate. Their results for Al ingested as Al citrate (0.7%) or Al citrate plus 76 mg of citrate (5%) are considerably larger than our median value of 0.16% for Al plus 20 mg of citric acid. The difference may be due to the different conditions of gavage (volume, pH, nature of citrate) or to the fact that the animals of Schö nholzer et al. were studied after a period of fast (private communication). Indeed, we have obtained results indicating that prior fasting substantially increases Al absorption [25] . Ittel et al. [24] found urinary excretion of 26 Al (administered with substantial quantities of 27 Al as AlCl 3 ) to be 0.032% and 0.018% in two rats. These are slightly lower than our values, even though their animals were in a fasted state. This is in contrast to Fink et al. [26] , measuring the accumulation of orally ingested 26 Al in the brains and livers of two 6-month-old Wistar rats (ϳ550 g), found results for brain (10 and 28 ϫ 10 Ϫ8 ) somewhat larger than our maximum value of 6.5 ϫ 10 Ϫ8 . Because Fink et al. do not give the total weight of the livers for their animals, an exact calculation of the fraction accumulated is not possible. However, estimating these weights as 4% of the rat body weight (i.e., 22 g) yields accumulation values of 8.8 ϫ 10
Ϫ6 and 33 ϫ 10 Ϫ6 , also somewhat larger than our median value of 2.2 ϫ 10 Ϫ6 . Although these estimates are based on only two measurements in their study, one reason for the differences could be the difference in age of the rats.
Walton et al. [27] also recently reported brain absorption factors for single doses of 26 Al administered orally to eight mature rats after a 30-h fast. Adopting the results from column 3 of their Table 1 [using the experimental results of their column 1, and the quantity of 27 Al carrier indicated in the paper (4 mg), we in fact calculate different values], we calculated that six of the rats had absorption factors for total brains of 0.5 ϫ 10 Ϫ8 to 4.5 ϫ 10
Ϫ8
-i.e., within the range found by us. Two other rats had considerably larger factors of 35 ϫ 10 Ϫ8 and 53 ϫ 10 Ϫ8 . Once again, the prolonged period of fasting may account for the enhanced absorption in these cases.
Several authors [18, 19, 28] have used serum concentrations of 26 Al to estimate aluminum absorption in humans. Our results in rats, however, show that the instantaneous amount of 26 Al present in the circulation at any time was never Ͼ10% of the total amount effectively absorbed. In studies of two human subjects, Hohl et al. [29] also found that the maximum 26 Al in circulation was never Ͼ20% of that excreted in urine. Therefore, in addition to requiring measurement of a complete time profile to ensure observation of the peak, estimates based on serum concentrations are likely to seriously underestimate total Al absorption.
One striking feature shown in Fig. 2 is that individual rats showing the largest urinary 26 Al excretion (e.g., rats 33 and 40) also tend to have the largest 26 Al retention in the organs studied. To examine this quantitatively, we calculated in Table 1 the ratio of retention in bone, brain, and liver to excretion in the urine. Interestingly, for the concomitant intake of citrate, these ratios are less variable than are the absolute retention factors themselves. Consequently, urinary excretion can be used to make reasonably reliable estimates of Al retention in other organs under physiological conditions. Similarly, although the concomitant ingestion of citrate increases Al absorption, Table 1 shows that this did not appear to modify the relative distribution of 26 Al in bone, brain, and liver in comparison with ingestion without citrate. This suggests that the critical step in Al retention is its initial passage through the gastrointestinal barrier.
From these data we draw the following conclusions. From the retention of Al in bone, liver, and brain and its excretion in urine, the gastrointestinal absorption of normal dietary quantities of Al by rats can be estimated as near 10 Ϫ3 (0.1%); however, this estimation does not take into account a possible distribution of Al into muscle. Because the amount of Al in the circulatory system never exceeds ϳ10% of that absorbed, blood samples are a poor indicator of gastrointestinal absorption of Al. About 50% of absorbed Al is rapidly (Ͻ2 h) and permanently (within the 30-day scale of our experiment) accumulated in the skeleton of young rats. About 50% of absorbed Al is excreted in urine, with 90% of this excretion occurring during the first 48 h after ingestion; this makes a 48-h sample of urine a relatively good indicator of total gastrointestinal absorption of Al. About 2 ϫ 10 Ϫ6 and 4 ϫ 10 Ϫ8 of ingested Al is permanently (within the 30 days of our experiment) deposited in the liver and brain, respectively. The concomitant intake of citrate leads to a more rapid, larger, and more variable absorption, with an average enhancement factor under our experimental conditions ranging from 2 to 5. Finally, the retention of Al in bone, brain, and liver, relative to that excreted in urine, is statistically indistinguishable between rats fed Al with citrate and those fed no citrate supplement (P Ͼ0.1); this suggests that the principal effect of citrate is to enhance gastrointestinal absorption, with little influence on subsequent distribution in various organs.
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